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Acetylcholinesterase inhibitors (AChEIs) are the most commonly prescribed monothera-  
peutic medications for Alzheimer’s disease (AD). However, their underlying neurophysio-  
logical effects remain largely unknown.We investigated the effects of monotherapy (AChEI)  
and combination therapy (AChEI and memantine) on brain reactivity and plasticity. Patients  
treated with monotherapy (AChEI) (N =7) were compared to patients receiving combina-  
tion therapy (COM) (N =9) and a group of age-matched, healthy controls (HCs) (N =13).  
 
Cortical reactivity and plasticity of the motor cortex were examined using transcranial mag-
 
netic stimulation. Cognitive functions were assessed with the cognitive subscale of the
 
Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), activities of daily
 
living (ADLs) with the ADCS-ADL. In addition we assessed the degree of brain atrophy by  
measuring brain-scalp distances in seven different brain areas. Patient groups differed in  
resting motor threshold and brain atrophy, with COM showing a lower motor threshold but  
less atrophy than AChEI. COM showed similar plasticity effects as the HC group, while  
plasticity was reduced in AChEI. Long-interval intracortical inhibition (LICI) was impaired  
in both patient groups when compared to HC. ADAS-Cog scores were positively corre-  
lated with LICI measures and with brain atrophy, specifically in the left inferior parietal  
cortex. AD patients treated with mono- or combination-therapy show distinct neurophysi-  
ological patterns. Further studies should investigate whether these measures might serve  
as biomarkers of treatment response and whether they could guide other therapeutic  
interventions.  
Keywords: Alzheimer’s disease, transcranial magnetic stimulation, brain plasticity, pharmacological therapy,
acetylcholinesterase inhibitors, memantine
INTRODUCTION
Alzheimer’s Disease (AD) is the most common form of dementia
and its treatment one of the most pressing medical issues. Current
therapeutic options are limited and underlying neurophysiologi-
cal mechanisms are still insufficiently understood. Available drugs
mainly target cholinergic and glutamatergic pathways.
The degeneration of cholinergic neurons in the basal fore-
brain is thought to extensively contribute to the cognitive decline
characteristic of AD (1). This led to the development of acetyl-
cholinesterase inhibitors (AChEIs), which slow down the break-
down of acetylcholine (ACh). The resulting increase of ACh in
affected forebrain regions is thought to improve cognitive func-
tions (2, 3). AChEIs currently in use for patients with mild to mod-
erate AD include donepezil (Aricept®), rivastigmine (Exelon®),
and galantamine (Razadyne®), all of which show similar efficacy
and side-effect profiles (4, 5).
The N -methyl-d-aspartate (NMDA) receptor antagonist
memantine (Namenda™) is traditionally used in moderate to
severe AD. At first sight it seems contradictory that blocking
NMDA receptors, which play a crucial role in synaptic plasticity
and therefore learning and memory, should prove efficacious in
AD. Yet, bearing in mind the importance of physiological balance,
both hyper- as well as hypoactivity of NMDA receptors leads to
dysfunctional effects (6). As NMDA receptors are hyperactive in
AD, memantine is used to re-balance glutamatergic pathways and
therefore reduce neurotoxic processes.
Clinical effects of both AChEI and memantine have been exten-
sively studied and include temporary and moderate improve-
ments in activities of daily living (ADLs), cognitive, and behav-
ioral functions (4, 7–9), and lead to a reduction of pathological
encephalographic rhythms (10).
Several pharmacological studies have shown inconsistent
results regarding the benefits of combining cholinesterase
inhibitors with memantine. Tariot et al. (11) found beneficial
effects of combination therapy, while consecutive studies showed
no additional benefit when memantine was added to a regime of
cholinesterase inhibitors (2, 12).
Transcranial magnetic stimulation (TMS) is a valuable tool to
investigate the neurophysiological effects of drugs. Previous stud-
ies have examined various TMS-measures in medicated healthy
subjects and in AD patients (13). In healthy subjects, memantine
reduces intracortical facilitation (ICF) and enhances short-interval
intracortical inhibition (SICI) in the motor cortex (MC) (14), and
results in reduced MC plasticity when administered over 8 days
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(15). This effect is likewise observed with the NMDA antago-
nist dextromethorphan (16). Memantine furthermore abolishes
inhibitory effects of continuous theta burst stimulation (cTBS)
and facilitatory effects of intermittent theta burst stimulation
(iTBS) on brain plasticity (17). AD patients treated with meman-
tine have not yet been investigated with TMS. AChEI given to
healthy subjects lead to reduced SICI and increased ICF and have
no effect on motor threshold and excitability (18). Contradictory
results have been found for the effect of AChEI on MC excitability
in AD patients. While one study found improvements in SICI after
administration of donepezil (19), another study did not find any
reversal in the progressive increase of excitability during 1 year of
treatment (20).
Rivastigmine furthermore leads to improvements of short
latency afferent inhibition (SAI), which is associated to long-term
treatment response (21). SAI is the most prominent TMS-measure
impaired in AD (13, 21–23). It is mediated through GABA-ergic
and cholinergic circuits (24), the latter of which plays a domi-
nant role in AD pathology. SAI is assessed by coupling TMS and
peripheral nerve stimulation of the contralateral wrist and has
inhibitory interactions with long-interval intracortical inhibition
(LICI) (25). To our knowledge, however, no study has investigated
LICI in AD patients.
In order to understand the possible mechanisms of action of
different pharmacological regimes, we evaluated MC excitability
and plasticity, ADLs, cognitive functions, and brain atrophy in two
groups of patients receiving either AChEI monotherapy or AChEI
combined with memantine. Findings were contrasted against an
age-matched healthy control (HC) group on no medications.
MATERIALS AND METHODS
SUBJECTS AND INCLUSION/EXCLUSION CRITERIA
We investigated 16 patients diagnosed with mild to moderate AD
(DSM IV, NINCDS-ADRDA): 7 were stable on AChEI (Table 1;
Figure 1), and 9 were treated with combination therapy (AChEI
and memantine). Patients were eligible if they had a score of
1 on the Clinical Dementia Rating scale (CDR), and attained
between 18 and 24 points on the Mini-Mental State Examination
(MMSE). Patients were recruited from other studies investigating
AD patients (ClinicalTrials.gov NCT01504958) in comparison to
older HCs. Patients were grouped according to psychopharmaco-
logical treatment. All experimenters were blinded with regards to
pharmacological treatment.
Alzheimer’s disease groups were compared to a group of 13
age-matched HCs with normal neurological and cognitive exams
and a score of 0 on the CDR. The local Institutional Review Board
approved the study protocol, and all participants or their legally
authorized representatives gave written informed consent prior to
study onset. The study visits took place at the Berenson-Allen
Center for Non-invasive Brain Stimulation and the Harvard-
Thorndike Clinical Research Center at Beth Israel Deaconess
Medical Center in Boston, MA, USA. Patients with unstable or
Table 1 | Demographic, pharmacological, neuropsychological, morphometric, and neurophysiological features of study participants.
AChEI and memantine
(N =9) mean±SD
AChEI (N =7)
mean±SD
pValue Healthy subjects (N =13)
mean±SD
pValue
Age (years) 71.78±3.73 68.00±7.55 0.351 67.762±6.05 0.278
Gender Six female, three male Five female, two male 1.000 Seven female, six male 0.700
Education (years) 15.33±3.97 17.71±3.90 0.470 15.77±2.17 0.659
Duration of disease (months) 38.00±34.90 16.43±15.51 0.071 – –
Duration of treatment (months) 33.00±34.76 15.57±16.26 0.244 – –
Brain-scalp distance mean (mm) 16.94±2.52 19.35±2.93 0.114 15.78±2.33 0.014
Brain-scalp distance left MC (mm) 15.67±2.02 19.38±3.78 0.042 14.47±1.80 0.007
Brain-scalp distance left IPL (mm) 21.98±5.35 26.39±6.51 0.125 18.03±2.82 0.023
rMT 36.83±6.53 50.38±8.16 0.001 45.26±11.98 0.012
aMT 39.96±6.07 48.43±10.39 0.055 44.89±8.01 0.112
MMSE 20.56±2.65 23.43±1.62 0.055 29.46±0.88 0.000
ADCS-ADL 68.57±5.22 72.29±6.47 0.209 74.62±3.59 0.043
GDS 2.22±2.54 1.71±2.06 0.918 0.69±1.11 0.202
ADAS-Cog 28.21±11.02 18.09±6.25 0.091 4.13±2.13 0.000
SICI 0.71±0.47 0.52±0.43 0.368 0.55±0.69 0.360
ICF 1.27±0.61 1.68±1.25 0.758 1.54±0.63 0.614
LICI 0.41±0.52 0.98±1.12 0.470 0.10±0.20 0.018
MC reactivity (µV) 1626±1418 1596±1558 0.758 17.71±3.90 0.907
Plasticity at T5 1.02±0.30 0.78±0.31 0.081 1.45±0.79 0.034
Mean plasticity 1.06±0.41 0.85±0.31 0.232 1.34±0.52 0.046
MC, motor cortex; IPL, inferior parietal lobule; rMT/aMT, resting/active motor threshold; MMSE, mini-mental state examination; ADCS-ADL, Alzheimer’s disease
cooperative study-activities of daily living inventory; GDS, geriatric depression scale; ADAS-Cog, Alzheimer’s disease assessment scale-cognitive subscale; SICI,
short-interval intracortical inhibition; ICF, intracortical facilitation; LICI, long-interval intracortical inhibition; p-values are two-tailed. Mann–Whitney U was used to
compare patient groups, Kruskal–Wallis was used to compare all three groups. Group values are presented as mean± standard deviation (SD). Bold font indicates
significant p-values.
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FIGURE 1 | Flow diagram of the enrollment process and final study participants analyzed.
chronic medical conditions, major structural or vascular abnor-
malities on MRI, severe agitation, functional psychiatric disorders,
a history of substance abuse or recent withdrawal, epilepsy, other
progressive neurological disorders, other diseases causing memory
impairment, or intake of drugs listed as a potential hazard for the
application of rTMS (26) were excluded from the study.
ASSESSMENTS
Brain excitability and plasticity, brain-scalp distances, the MMSE,
(ADCS-ADL), and the Geriatric Depression Scale (GDS) were
assessed by trained research personnel. Certified neuropsychol-
ogists and neurologists assessed Alzheimer disease assessment
scale-cognitive subscale (ADAS-Cog) and CDR.
MAPPING, BRAIN REACTIVITY, AND PLASTICITY MEASURES
The Nexstim system (eXimia NBS 4) was used for neuronavigated
single- and paired-pulse stimulation over the left MC. Resting
motor threshold (rMT) was defined as the minimum stimulation
intensity required to elicit a motor evoked potential (MEP) in the
first dorsal interosseous muscle (FDI) of at least 50µV in 5 out of
10 trials. Active motor threshold (aMT) was defined as the min-
imal stimulation intensity required to elicit an MEP in 5 out of
10 trials during isometric contraction of the FDI muscle. MEPs
were recorded using 30 mm× 22 mm, wet gel surface electrodes
(Ambu). The active electrode was placed over the muscle belly and
the reference electrode over the proximal interphalangeal joint of
the index finger.
Stimulation intensity for single-pulse TMS was set to 120% of
rMT. For paired-pulse TMS, intensity was set to 80% rMT for the
conditioning pulse and 120% rMT for the test pulse, with an inter-
pulse interval of 3 ms to determine SICI and 12 ms to determine
ICF. Two pulses at 120% rMT with an inter-pulse interval of 100 ms
were used to determine LICI. Paired-pulse measures (each set 50
paired-pulses) were expressed as the ratio of the mean conditioned
MEP amplitude to the mean unconditioned MEP amplitude.
To assess the mechanisms of cortical plasticity, neuronavigated
intermittent theta burst stimulation (iTBS) was applied using the
MagPro X100 (MagVenture). Baseline single-pulse stimulations
(90 pulses at 120% rMT with biphasic coil) were followed by iTBS
(600 pulses in 2 s trains at 50 Hz repeated every 10 s; stimulation
intensity set to 80% of aMT). Sets of 30 single-pulses were deliv-
ered at 120% rMT at distinct time periods post iTBS (after 5, 10,
20, 30, 60, and 90 min).
Brain reactivity was defined as the average amplitude of 90
single-pulse MEPs at baseline; brain plasticity was expressed as
the ratio of averaged MEP amplitudes obtained at each of the time
points after iTBS to the mean baseline MEP amplitude. Safety
guidelines were strictly followed (26).
BRAIN-SCALP DISTANCE MEASUREMENTS
As an index of brain atrophy, brain-scalp distances were mea-
sured on each individual’s brain MRI (Brainsight) in seven brain
regions: left hand MC, right and left dorsolateral prefrontal cortex
(DLPFC), right and left inferior parietal cortex (IPL), left supe-
rior temporal gyrus (STG), and left inferior frontal gyrus (IFG).
Brain regions were determined using conventional Talairach/MNI
coordinates (27–29). For each brain region, three measurements
were taken in both the coronal and sagittal view, and the six
measurements were averaged for each region (28).
DATA ANALYSIS
Data was analyzed using non-parametric tests (SPSS 19.0 for Mac)
with the statistical significance set at p< 0.05. Group compar-
isons were calculated with the Kruskal–Wallis test, Mann–Whitney
U tests served as post hoc tests. Correlations were calculated
using Kendall’s tau. p-Values are two-tailed. As this study was an
exploratory trial, a formal sample size analysis was not possible.
RESULTS
GROUP EFFECTS
Patient groups did not differ significantly in age, gender, educa-
tion years, duration of disease or pharmacologic treatment, mean
brain-scalp distance, MMSE, ADCS-ADL, GDS, or ADAS-Cog
scores (Table 1).
Acetylcholinesterase inhibitor, COM, and HC did not dif-
fer significantly regarding age, gender, education years, or
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GDS. However, the three groups differed significantly in rMT
[H (2)= 8.857, p= 0.012], brain plasticity at T5 [H (2)= 6.782,
p= 0.034], and in average degree of TBS-induced plastic-
ity over all time points [H (2)= 6.146, p= 0.046]. Further-
more, a significant group difference was found for LICI
[H (2)= 8.003, p= 0.018] (Figure 2). Brain-scalp distances were
significantly different between groups when averaged over all
regions [H (2)= 8.551, p= 0.014], but particularly for left IPL
[H (2)= 7.582,p= 0.023], and left MC [H (2)= 9.852, p= 0.007].
In the cognitive and behavioral assessments, groups differed sig-
nificantly in ADAS-Cog scores [H (2)= 21.713,p< 0.001], MMSE
[H (2)= 22.675, p< 0.001], and ADCS-ADL [H (2)= 6.316,
p= 0.043] (Figure 3).
POST HOC GROUP COMPARISONS
Motor thresholds, brain reactivity and plasticity, brain atrophy
Post hoc tests revealed a significantly lower rMT in COM as com-
pared to AChEI (U = 60.00, z = 3.02, p= 0.001), while rMTs of
both patient groups and HC were comparable (Figure 2A). HC
showed greater plasticity at T5 (U = 73.00, z = 2.18, p= 0.030),
T20 (U = 74.00, z = 2.26, p= 0.024), T60 (U = 71.00, z = 2.02,
p= 0.046), and at an average of all time points (U = 78.00,
z = 2.58, p= 0.008) when compared with AChEI. COM and
HC did not differ significantly in TBS-induced brain plas-
ticity (Figure 2B). LICI was significantly reduced in both
COM (U = 20.00, z =−2.24, p= 0.025) and AChEI (U = 12.00,
z =−2.40, p= 0.015) as compared to HC (Figure 2C).
Acetylcholinesterase inhibitor showed greater atrophy as com-
pared to HC in all three measures: averaged atrophy (U = 9.00,
z =−2.89, p= 0.002), left IPL (U = 15.00, z =−2.42, p= 0.014),
and MC (U = 7.00, z =−3.05, p= 0.001). However, AChEI also
showed a significantly greater atrophy in MC as compared to COM
(U = 51.00, z = 2.06, p= 0.042). COM did not differ from HC in
atrophy (Figure 3A).
ADAS-Cog, MMSE, ADL, GDS
Alzheimer disease assessment scale-cognitive subscale and MMSE
scores were significantly different from HC in both AChEI (ADAS-
Cog: U = 0.00, z =−3.61, p< 0.001; MMSE: U = 91.00, z = 3.75,
p< 0.001) and COM (ADAS-Cog:U = 0.00,z =−3.91,p< 0.001;
MMSE: U = 117.00, z = 4.02, p< 0.001) (Figure 3B). COM
was significantly more impaired than HC (U = 78.00, z = 2.60,
p= 0.008) in ADCS-ADL, while HC and AChEI did not show
significant differences (Figure 3C).
CORRELATIONS (AD AND HC)
Alzheimer disease assessment scale-cognitive subscale scores
were significantly correlated with LICI (τ= 0.352, p= 0.010)
(Figure 4A) and with mean atrophy over seven brain regions
(τ= 0.304, p= 0.021), specifically with atrophy of the left IPL
(τ= 0.277, p= 0.036). Brain-scalp distance in MC was cor-
related with rMT (τ= 0.287, p= 0.029) and aMT (τ= 0.319,
p= 0.015) and mean brain-scalp distance was correlated with rMT
(τ= 0.297, p= 0.024). RMT was correlated with aMT (τ= 0.688,
FIGURE 2 |TMS-driven measures of corticomotor reactivity and
plasticity in Alzheimer’s patients treated with acetylcholinesterase
inhibitors (AChEI) or a combination of AChEI and memantine (COM),
and a healthy age-matched control group (HC). (A) Resting motor
threshold measured from the first dorsal interosseus muscle (mean±SE).
(B) Brain plasticity measures (mean±SE) over a time-period of 90 min post
iTBS. (C) Paired-pulse TMS-measures of long-interval intracortical inhibition
(LICI).
FIGURE 3 | Morphometric, neuropsychological, and behavioral measures of AChEI, COM, and HC. (A) Brain atrophy as indicated by brain-scalp distances
obtained from seven different brain areas (mean±SE). (B) ADAS-Cog scores (mean±SE). (C) ADCS-ADL scores (mean±SE).
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FIGURE 4 | (A) Correlation between long-interval intracortical inhibition (LICI)
and ADAS-Cog scores of all study participants. Higher ADAS-Cog scores
indicate more dysfunction. (B) Correlation between average brain plasticity
within 90 min after intermittent theta burst stimulation (iTBS) and time since
diagnosis. (C) Correlation between average brain plasticity and time since
medication onset.
p< 0.001), SICI (τ=−0.476, p= 0.001), and ICF (τ=−0.316,
p= 0.022). Interestingly, disease duration was positively cor-
related with average plasticity measures (τ= 0.456, p= 0.019),
specifically at T20 (τ= 0.441, p= 0.019). Time since medica-
tion intake was also positively correlated with average plastic-
ity measures (τ= 0.402, p= 0.037). After removal of one out-
lier correlations remained significant for both disease duration
(τ= 0.437, p= 0.025) (Figure 4B) and time since medication
onset (τ= 0.388, p= 0.047) (Figure 4C).
DISCUSSION
We investigated the impact of pharmacological monotherapy
(AChEI) and combined interventions (AChEI and memantine)
on neurophysiological indices of brain reactivity and plasticity
in patients with AD and age-matched HCs. Neurophysiological
findings were related to cognitive function, disease duration, and
measures of brain atrophy.
Patient groups showed differences in rMT and brain atrophy in
MC, with COM showing lower motor thresholds but less atrophy
than AChEI. Since the current induced by TMS decreases steeply
with distance, a greater atrophy would be expected to result in
higher MTs. Yet, most studies to date report lower MTs indicat-
ing higher motor cortical excitability in AD patients (13), but also
opposite effects have been found (30). Differences in MT between
COM and AChEI might therefore simply reflect differences in the
degree of brain atrophy. Nonetheless, this is somewhat surpris-
ing, since greater atrophy would be expected to indicate more
progressed disease stage, which might lead to the combination
therapy, rather than be found in patients on monotherapy. Dis-
ease duration in COM and AChEI was however not significantly
different. The addition of memantine to a regime of AChEI may
therefore possibly slow down progression of atrophy; a research
question that warrants further studies.
Measures of plasticity showed differences between COM and
AChEI patients. COM showed similar plasticity effects as the
HC group, while plasticity was reduced in AChEI. This is in
line with a previous study (31) showing impaired brain plastic-
ity in AD patients. We found no indication that the reduction
in plasticity could be related to the greater atrophy in the left
MC measured in AChEI. Future studies need to carefully control
for atrophy and adjust stimulation intensity accordingly. How-
ever, our results suggest that atrophy does not account for the
observed changes in plasticity or the implied medication effects.
Disease duration, as expected, was correlated with degree of atro-
phy. Nonetheless, unexpectedly, we found that plasticity measures
positively correlated with duration of disease and time since med-
ication intake. Our data do not allow us to disentangle whether
this unexpected finding is related to the duration of the disease
or the medication treatment itself. The possibility that medica-
tion treatment might reverse an age- and disease-related trend for
progressive loss of efficacy of plasticity mechanisms is intrigu-
ing. Longitudinal studies would be important to address this
question.
Long-interval intracortical inhibition was the only measure
that was impaired in both patient groups when compared to
HC. To our knowledge this is the first study investigating LICI
in AD patients. LICI and SAI have inhibitory interactions (25),
which may explain our findings. SAI has been singled out as a
measure reliably reduced in AD [e.g., Ref. (32)] and is a predic-
tor of memory dysfunctions (33). Nonetheless, the mechanisms
remain unclear. Evidence shows that LICI is mediated through
long-lasting GABAB-dependent inhibitory postsynaptic poten-
tials (IPSPs) and activation of pre-synaptic GABAB receptors
on inhibitory interneurons (34). Interactions between choliner-
gic and GABA-ergic pathways may account for our finding (35).
Cognitive functions were not only positively correlated with LICI
measures but also with brain atrophy, specifically in the left IPL,
an area which has been previously shown to be affected early and
prominently in AD patients (36). In future studies, the use of TMS
combined with electroencephalography (EEG) would offer a valu-
able means to investigate cortical reactivity and plasticity directly
in IPL and relate neurophysiological and anatomical findings more
directly.
Cognitive impairments in AD have been linked to cholinergic
dysfunctions (1), on the other hand, glutamate receptor hyperac-
tivity leads to neurotoxic effects and contributes to brain atrophy
(37). Studies investigating effects of memantine on brain atrophy
show contradictory results. Wilkinson et al. (3) did not report any
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differences, while Weiner et al. (38) found that adding meman-
tine to the AChEI regimen led to slowing of atrophic processes
in the hippocampus and cognitive improvements. In our study,
COM showed less brain atrophy and less plasticity aberrations
than AChEI, yet they did not display better cognitive functioning
or behavioral outcomes. A limitation of this study is the moderate
sample size. Differences between COM and AChEI in disease dura-
tion and cognitive outcomes may therefore not be fully captured.
Further prospective studies aimed at elucidating the underlying
neurophysiological mechanisms of AChEI, memantine, and COM
seem important, and may allow us to capitalize on pharmaco-
logically induced physiological changes, which may be used to
enhance therapeutic effects of interventions aimed at improving
learning and memory, such as cognitive therapy or synergistic cog-
nitive therapy and non-invasive brain stimulation. Future studies
should moreover combine TMS with EEG in order to investigate
the impact of different pharmacological regimens on brain regions
outside the MC. Furthermore, brain plasticity should be measured
at the onset of pharmacological treatment as well as throughout
the course of the disease.
In sum, our results suggest that different pharmacological ther-
apies can entail differential neurophysiological effects, which could
affect cognitive and behavioral outcomes.
AUTHOR CONTRIBUTIONS
Anna-Katharine Brem, Natasha J. Atkinson, and Erica E. Selig-
son prepared the draft report together with Alvaro Pascual-Leone,
which was critically reviewed by all authors. Anna-Katharine
Brem, Natasha J. Atkinson, and Erica E. Seligson analyzed the data
and contributed to data collection.
ACKNOWLEDGMENTS
We thank Lukas Schilberg, B.Sc., Catarina Freitas, Ph.D., Rain
Thomas, Léonie Asboth, M.Sc., Edward Gold, Christina Carbone,
Ilya Vidrin, Cory Kosche, Jessica Olson, Fritz Ifert-Miller, and
Zachary Gray for their support in data collection; Lisa Iguchi,
Ph.D. for the neuropsychological exams; Ann Connor, RN, MS
for help with patient assessments and study oversight, and Drs.
Daniel Press, MD and Mark Eldaief, MD for assistance with the
neurological exams. Funding sources: Work on this study was
supported by a grant from the National Institutes of Health – Har-
vard Clinical and Translational Science Center/Harvard Catalyst
(UL1 RR025758), and investigator-initiated grants from Nexstim
Inc., and Neuronix. Dr. Brem was supported by the Young Aca-
demics Support and the Stiefel-Zangger Foundation of the Uni-
versity of Zurich, Switzerland, and the Swiss National Foundation
(PBZHP1_147196).
REFERENCES
1. Bartus RT, Dean RL III, Beer B,
Lippa AS. The cholinergic hypothe-
sis of geriatric memory dysfunction.
Science (1982) 217:408–14. doi:10.
1126/science.7046051
2. Howard R, McShane R, Linde-
say J, Ritchie C, Baldwin A,
Barber R, et al. Donepezil and
memantine for moderate-to-severe
Alzheimer’s disease. N Engl J Med
(2012) 366:893–903. doi:10.1056/
NEJMoa1106668
3. Wilkinson D, Schindler R, Schwam
E, Waldemar G, Jones RW, Gauthier
S, et al. Effectiveness of donepezil
in reducing clinical worsening
in patients with mild-to-moderate
Alzheimer’s disease. Dement Geri-
atr Cogn Disord (2009) 28:244–51.
doi:10.1159/000241877
4. Birks J. Cholinesterase inhibitors for
Alzheimer’s disease.Cochrane Data-
base Syst Rev (2006) (1). doi:10.
1002/14651858.CD005593
5. Hansen RA, Gartlehner G, Webb
AP, Morgan LC, Moore CG, Jonas
DE. Efficacy and safety of donepezil,
galantamine, and rivastigmine for
the treatment of Alzheimer’s dis-
ease: a systematic review and meta-
analysis. Clin Interv Aging (2008)
3:211–25.
6. Parsons CG, Stöffler A, Danysz
W. Memantine: a NMDA recep-
tor antagonist that improves mem-
ory by restoration of homeostasis
in the glutamatergic system – too
little activation is bad, too much
is even worse. Neuropharmacology
(2007) 53:699–723. doi:10.1016/j.
neuropharm.2007.07.013
7. McShane R, Areosa Sastre A,
Minakaran N. Memantine for
dementia. Cochrane Database
Syst Rev (2006) (2). doi:10.1002/
14651858.CD003154.pub5
8. Winblad B, Gauthier S, Aström
D, Stender K. Memantine benefits
functional abilities in moderate to
severe Alzheimer’s disease. J Nutr
Health Aging (2010) 14:770–4. doi:
10.1007/s12603-010-0122-x
9. Yang Z, Zhou X, Zhang Q. Effec-
tiveness and safety of memantine
treatment for Alzheimer’s disease.
J Alzheimers Dis (2013) 36:445–58.
doi:10.3233/JAD-130395
10. Babiloni C, Del Percio C, Bor-
det R, Bourriez J-L, Bentivoglio
M, Payoux P, et al. Effects of
acetylcholinesterase inhibitors and
memantine on resting-state elec-
troencephalographic rhythms in
Alzheimer’s disease patients. Clin
Neurophysiol (2013) 124:837–50.
doi:10.1016/j.clinph.2012.09.017
11. Tariot PN, Farlow MR, Grossberg
GT, Graham SM, McDonald S,
Gergel I, et al. Memantine treatment
in patients with moderate to severe
Alzheimer disease already receiving
donepezil: a randomized controlled
trial. JAMA (2004) 291:317–24. doi:
10.1001/jama.291.3.317
12. Porsteinsson AP, Grossberg GT,
Mintzer J, Olin JT; Meman-
tine MEM-MD-12 Study
Group. Memantine treatment
in patients with mild to moderate
Alzheimer’s disease already receiv-
ing a cholinesterase inhibitor:
a randomized, double-blind,
placebo-controlled trial. Curr
Alzheimer Res (2008) 5:83–9.
doi:10.2174/156720508783884576
13. Freitas C, Mondragón-Llorca H,
Pascual-Leone A. Noninvasive brain
stimulation in Alzheimer’s disease:
systematic review and perspec-
tives for the future. Exp Geron-
tol (2011) 46:611–27. doi:10.1016/
j.exger.2011.04.001
14. Schwenkreis P, Witscher K, Janssen
F, Addo A, Dertwinkel R, Zenz M,
et al. Influence of the N-methyl-D-
aspartate antagonist memantine on
human motor cortex excitability.
Neurosci Lett (1999) 270:137–40.
doi:10.1016/S0304-3940(99)
00492-9
15. Schwenkreis P, Witscher K, Pleger
B, Malin J-P, Tegenthoff M. The
NMDA antagonist memantine
affects training induced motor
cortex plasticity – a study using
transcranial magnetic stimula-
tion. BMC Neurosci (2005) 6:35.
doi:10.1186/1471-2202-6-35
16. Ziemann U, Chen R, Cohen
LG, Hallett M. Dextromethor-
phan decreases the excitability of
the human motor cortex. Neurol-
ogy (1998) 51:1320–4. doi:10.1212/
WNL.51.5.1320
17. Huang Y-Z, Chen R-S, Rothwell JC,
Wen H-Y. The after-effect of human
theta burst stimulation is NMDA
receptor dependent. Clin Neuro-
physiol (2007) 118:1028–32. doi:10.
1016/j.clinph.2007.01.021
18. Korchounov A, Ilic TV, Schwinge T,
Ziemann U. Modification of motor
cortical excitability by an acetyl-
cholinesterase inhibitor. Exp Brain
Res (2005) 164:399–405. doi:10.
1007/s00221-005-2326-6
19. Liepert J, Bär KJ, Meske U, Weiller
C. Motor cortex disinhibition in
Alzheimer’s disease. Clin Neu-
rophysiol (2001) 112:1436–41.
doi:10.1016/S1388-2457(01)
00554-5
20. Pennisi G, Alagona G, Ferri R,
Greco S, Santonocito D, Pappalardo
A, et al. Motor cortex excitabil-
ity in Alzheimer disease: one
year follow-up study. Neurosci
Lett (2002) 329:293–6. doi:10.1016/
S0304-3940(02)00701-2
21. Di Lazzaro V, Oliviero A, Pilato
F, Saturno E, Dileone M, Marra
C, et al. Neurophysiological pre-
dictors of long term response to
AChE inhibitors in AD patients. J
Neurol Neurosurg Psychiatry (2005)
76:1064–9. doi:10.1136/jnnp.2004.
051334
22. Di Lazzaro V, Oliviero A, Tonali
PA, Marra C, Daniele A, Profice P,
et al. Noninvasive in vivo assess-
ment of cholinergic cortical cir-
cuits in AD using transcranial mag-
netic stimulation. Neurology (2002)
59:392–7. doi:10.1212/WNL.59.3.
392
Frontiers in Psychiatry | Neurodegeneration October 2013 | Volume 4 | Article 124 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brem et al. Pharmacological effects in AD
23. Nardone R,Golaszewski S,Ladurner
G, Tezzon F, Trinka E. A review
of transcranial magnetic stimula-
tion in the in vivo functional evalua-
tion of central cholinergic circuits in
dementia.DementGeriatrCognDis-
ord (2011) 32:18–25. doi:10.1159/
000330016
24. Di Lazzaro V, Oliviero A, Profice P,
Pennisi MA, Di Giovanni S, Zito
G, et al. Muscarinic receptor block-
ade has differential effects on the
excitability of intracortical circuits
in the human motor cortex. Exp
Brain Res (2000) 135:455–61. doi:
10.1007/s002210000543
25. Udupa K, Ni Z, Gunraj C, Chen R
Interactions between short latency
afferent inhibition and long inter-
val intracortical inhibition. Exp
Brain Res (2009) 199:177–83. doi:
10.1007/s00221-009-1997-9
26. Rossi S, Hallett M, Rossini PM,
Pascual-Leone A. Safety, ethical con-
siderations, and application guide-
lines for the use of transcranial mag-
netic stimulation in clinical prac-
tice and research. Clin Neurophysiol
(2009) 120:2008–39. doi:10.1016/j.
clinph.2009.08.016
27. Price CJ, Winterburn D, Giraud
AL, Moore CJ, Noppeney U.
Cortical localisation of the visual
and auditory word form areas: a
reconsideration of the evidence.
Brain Lang (2003) 86:272–86.
doi:10.1016/S0093-934X(02)
00544-8
28. Rusjan PM, Barr MS, Farzan F,
Arenovich T, Maller JJ, Fitzgerald
PB, et al. Optimal transcranial
magnetic stimulation coil place-
ment for targeting the dorsolat-
eral prefrontal cortex using novel
magnetic resonance image-guided
neuronavigation. Hum Brain Mapp
(2010) 31:1643–52. doi:10.1002/
hbm.20964
29. Sajonz B, Kahnt T, Margulies DS,
Park SQ, Wittmann A, Stoy M, et al.
Delineating self-referential process-
ing from episodic memory retrieval:
common and dissociable networks.
Neuroimage (2010) 50:1606–17.
doi:10.1016/j.neuroimage.2010.01.
087
30. Perretti A, Grossi D, Fragassi N,
Lanzillo B, Nolano M, Pisacreta AI,
et al. Evaluation of the motor cortex
by magnetic stimulation in patients
with Alzheimer disease. J Neurol Sci
(1996) 135:31–7. doi:10.1016/0022-
510X(95)00244-V
31. Koch G, Di Lorenzo F, Bonní S,
Ponzo V, Caltagirone C, Martorana
A. Impaired LTP- but not LTD-
like cortical plasticity in Alzheimer’s
disease patients. J Alzheimers Dis
(2012) 31:593–9.
32. Di Lazzaro V, Pilato F, Dileone
M, Saturno E, Oliviero A, Marra
C, et al. In vivo cholinergic
circuit evaluation in frontotem-
poral and Alzheimer dementias.
Neurology (2006) 66:1111–3.
doi:10.1212/01.wnl.0000204183.
26231.23
33. Young-Bernier M, Kamil Y, Trem-
blay F, Davidson PSR. Associa-
tions between a neurophysiological
marker of central cholinergic activ-
ity and cognitive functions in young
and older adults. Behav Brain
Funct (2012) 8:17. doi:10.1186/
1744-9081-8-17
34. McDonnell MN, Orekhov Y, Zie-
mann U. The role of GABA(B)
receptors in intracortical inhibition
in the human motor cortex. Exp
Brain Res (2006) 173:86–93. doi:10.
1007/s00221-006-0365-2
35. Anderson JJ, Kuo S, Chase TN, Eng-
ber TM. GABAA and GABAB recep-
tors differentially regulate striatal
acetylcholine release in vivo. Neu-
rosci Lett (1993) 160:126–30. doi:
10.1016/0304-3940(93)90395-2
36. Im K, Lee J-M, Seo SW, Yoon
U, Kim ST, Kim Y-H, et al. Vari-
ations in cortical thickness with
dementia severity in Alzheimer’s
disease. Neurosci Lett (2008) 436:
227–31. doi:10.1016/j.neulet.2008.
03.032
37. Meier-Ruge WA, Bertoni-Freddari
C. Pathogenesis of decreased
glucose turnover and oxidative
phosphorylation in ischemic and
trauma-induced dementia of the
Alzheimer type. Ann N Y Acad Sci
(1997) 826:229–41. doi:10.1111/j.
1749-6632.1997.tb48474.x
38. Weiner MW, Sadowsky C, Sax-
ton J, Hofbauer RK, Graham SM,
Yu SY, et al. Magnetic resonance
imaging and neuropsychological
results from a trial of memantine
in Alzheimer’s disease. Alzheimers
Dement (2011) 7:425–35. doi:10.
1016/j.jalz.2010.09.003
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or financial relationships
that could be construed as a poten-
tial conflict of interest. Alvaro Pascual-
Leone serves on the scientific advisory
boards for Nexstim, Neuronix, Starlab
Neuroscience, Neuroelectrics, and Neo-
Sync; and is listed as an inventor on
several issued and pending patents on
the real-time integration of transcranial
magnetic stimulation (TMS) with elec-
troencephalography (EEG) and mag-
netic resonance imaging (MRI).
Received: 31 July 2013; accepted: 21 Sep-
tember 2013; published online: 07 Octo-
ber 2013.
Citation: Brem A-K, Atkinson NJ, Selig-
son EE and Pascual-Leone A (2013) Dif-
ferential pharmacological effects on brain
reactivity and plasticity in Alzheimer’s
disease. Front. Psychiatry 4:124. doi:
10.3389/fpsyt.2013.00124
This article was submitted to Neurode-
generation, a section of the journal Fron-
tiers in Psychiatry.
Copyright © 2013 Brem, Atkinson, Selig-
son and Pascual-Leone. This is an open-
access article distributed under the terms
of the Creative Commons Attribution
License (CC BY). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) or licensor
are credited and that the original publica-
tion in this journal is cited, in accordance
with accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.
www.frontiersin.org October 2013 | Volume 4 | Article 124 | 7
